Cyclophosphamide Injection
NDC 55150-271
Product Information
Cyclophosphamide is a NDA-approved product labeled by Eugia Us Llc. Cyclophosphamide is used to treat various types of cancer. It is supplied as a injection for intravenous administration. This product entry covers the primary NDC 55150-271 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 55150-271?
What are the uses of this product?
What are Active Ingredients of this product?
- CYCLOPHOSPHAMIDE 1 g/5mL - Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CYCLOPHOSPHAMIDE (UNII: 8N3DW7272P)
- CYCLOPHOSPHAMIDE ANHYDROUS (UNII: 6UXW23996M) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)
- ALCOHOL (UNII: 3K9958V90M)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2386859 - cycloPHOSphamide 200 MG/ML Injectable Solution
- RxCUI: 2386859 - cyclophosphamide 200 MG/ML Injectable Solution
- RxCUI: 2568661 - cycloPHOSphamide 1 G in 5 ML Injection
- RxCUI: 2568661 - 5 ML cyclophosphamide 200 MG/ML Injection
- RxCUI: 2568661 - cyclophosphamide 1 G per 5 ML Injection
* Please review the full disclaimer at the bottom of this page.
Patient Education
Cyclophosphamide Injection
Cyclophosphamide is used alone or in combination with other medications to treat Hodgkin's lymphoma (Hodgkin's disease) and non-Hodgkin's lymphoma (types of cancer that begin in a type of white blood cells that normally fights infection); cutaneous T-cell lymphoma (CTCL, a group of cancers of the immune system that first appear as skin rashes); multiple myeloma (a type of cancer of the bone marrow); and certain types of leukemia (cancer of the white blood cells), including chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute myeloid leukemia (AML, ANLL), and acute lymphoblastic leukemia (ALL). It is also used to treat retinoblastoma (cancer in the eye), neuroblastoma (a cancer that begins in nerve cells and occurs mainly in children), ovarian cancer (cancer that begins in the female reproductive organs where eggs are formed), and breast cancer. Cyclophosphamide is also used to treat nephrotic syndrome (a disease that is caused by damage to the kidneys) in children whose disease has not improved, has gotten worse, or has come back after taking other medications or in children who experienced intolerable side effects with other medications. Cyclophosphamide is in a class of medications called alkylating agents. When cyclophosphamide is used to treat cancer, it works by slowing or stopping the growth of cancer cells in your body. When cyclophosphamide is used to treat nephrotic syndrome, it works by suppressing your body's immune system.
[Learn More]
* Please review the full disclaimer at the bottom of this page.